Reply to the letter of Mahajan and Gaur in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.).
In: Diabetes & metabolic syndrome, Jg. 14 (2020-09-01), Heft 5, S. 729
editorialOpinion
Zugriff:
Titel: |
Reply to the letter of Mahajan and Gaur in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.).
|
---|---|
Autor/in / Beteiligte Person: | Singh, AK ; Gupta, R ; Misra, A |
Zeitschrift: | Diabetes & metabolic syndrome, Jg. 14 (2020-09-01), Heft 5, S. 729 |
Veröffentlichung: | Amsterdam : Elsevier Ltd., 2020 |
Medientyp: | editorialOpinion |
ISSN: | 1878-0334 (electronic) |
DOI: | 10.1016/j.dsx.2020.05.030 |
Schlagwort: |
|
Sonstiges: |
|